therapeutics

Rakovina Therapeutics Announces Three-Month Q2 ended June 30, 2025 Financial Results and Provides Corporate Update

All dollar amounts reflected in Canadian dollars unless otherwise stated August 28, 2025 18:12 ET  | Source: Rakovina Therapeutics Inc…

3 months ago

Cognition Therapeutics Announces $30 Million Registered Direct Offering of Common Stock

August 27, 2025 20:53 ET  | Source: Cognition Therapeutics, Inc. - The offering was made to two new fundamental institutional…

3 months ago

Vivoryon Therapeutics N.V. to Report H1 2025 Financial Results and Operational Progress on September 4, 2025

Vivoryon Therapeutics N.V. to Report H1 2025 Financial Results and Operational Progress on September 4, 2025 Halle (Saale) / Munich,…

3 months ago

Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships

    - Successfully initiated enrollment in advanced Phase 2 ovarian cancer trial - Expanded global IP protection by securing…

4 months ago

Plus Therapeutics Reports Stockholders Equityin Excess of $2.5 million in Compliance with Nasdaq Equity Requirements

August 15, 2025 07:30 ET  | Source: Plus Therapeutics Inc. HOUSTON, Aug. 15, 2025 (GLOBE NEWSWIRE) --  Plus Therapeutics, Inc.…

4 months ago

Revive Therapeutics Announces Closing of First Tranche of Private Placement and Debt Settlement

TORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R),…

4 months ago

Purespring Therapeutics receives UK CTA approval for Phase I/II clinical trial of PS-002 in patients with primary IgA nephropathy (IgAN)

First patient in Phase I/II clinical trial expected to be enrolled in Q4 2025UK Clinical Trial Application (CTA) approval shortly…

4 months ago

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 01, 2025 16:08 ET  | Source: Protara Therapeutics NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc.…

4 months ago

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 01, 2025 16:05 ET  | Source: Akebia Therapeutics, Inc. CAMBRIDGE, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®,…

4 months ago

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 01, 2025 16:30 ET  | Source: Xilio Therapeutics, Inc. WALTHAM, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics,…

4 months ago